Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

232.04 +4.63 (+2.04%)
Streaming Delayed Price Updated: 3:52 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 892,644
Open 228.00
Bid (Size) 231.99 (2)
Ask (Size) 232.13 (2)
Prev. Close 227.41
Today's Range 227.41 - 234.06
52wk Range 220.86 - 319.76
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Comparative Study: Biogen And Industry Competitors In Biotechnology Industry
Via Benzinga
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this  
Via Benzinga

Performance

YTD
-14.89%
-14.89%
1 Month
-2.18%
-2.18%
3 Month
-13.42%
-13.42%
6 Month
-22.31%
-22.31%
1 Year
-20.51%
-20.51%

More News

Read More
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Via Investor's Business Daily
Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today
Via Benzinga
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry
Via Benzinga
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
Via Investor's Business Daily
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
Via The Motley Fool
These Analysts Revise Their Forecasts On Biogen After Q3 Results
Via Benzinga
Expert Ratings for Biogen
Via Benzinga
Thoughts For Thursday: Staying On Top - Barely
Via Talk Markets
Biogen (BIIB) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides
Via Benzinga
Looking Into Biogen's Recent Short Interest
Via Benzinga
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years
Via Benzinga
Assessing Biogen's Performance Against Competitors In Biotechnology Industry
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Compared To Estimates, Biogen Inc. Q3 Earnings: A Look At Key Metrics
Via Talk Markets
US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount
Via Investor's Business Daily
3 Biotech Moonshots to Bet on the Future of Health
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Biogen Appoints Monish Patolawala to its Board of Directors
From Biogen Inc.
Via GlobeNewswire
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment
Via Investor's Business Daily
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On
From Biogen Inc.
Via GlobeNewswire
Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease
Via Benzinga
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.